{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:23:31Z","timestamp":1770884611621,"version":"3.50.1"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2018.00718","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T05:12:56Z","timestamp":1545109976000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Risperidone-Associated Neuroleptic Malignant Syndrome in an Inpatient With Schizophrenia, With Successful Rechallenge and 3 Year Follow-Up"],"prefix":"10.3389","volume":"9","author":[{"given":"Ting-Ren","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/00002018\u2013199819010-00006","article-title":"Neuroleptic malignant syndrome. Recognition, prevention and management","volume":"19","author":"Velamoor","year":"1998","journal-title":"Drug Saf"},{"key":"B2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2174\/1570159X13999150424113345","article-title":"Neuroleptic malignant syndrome: a review from a clinically oriented perspective","volume":"13","author":"Tse","year":"2015","journal-title":"Curr Neuropharmacol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1176\/ajp.2007.164.6.870","article-title":"Neuroleptic malignant syndrome","volume":"164","author":"Strawn","year":"2007","journal-title":"Am J Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00213\u2013014-3807\u20138","article-title":"Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma","volume":"232","author":"Lang","year":"2015","journal-title":"Psychopharmacology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/B978\u20130-444\u201364074-1.00039\u20132","article-title":"Neuroleptic malignant syndrome and serotonin syndrome","volume":"157","author":"Tormoehlen","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"B6","first-page":"18","article-title":"Mortality from neuroleptic malignant syndrome","volume":"50","author":"Shalev","year":"1989","journal-title":"J Clin Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/00005053\u2013199403000-00007","article-title":"Progression of symptoms in neuroleptic malignant syndrome","volume":"182","author":"Velamoor","year":"1994","journal-title":"J Nerv Ment Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1017\/S1461145799001388","article-title":"Proposed research diagnostic criteria for neuroleptic malignant syndrome","volume":"2","author":"Mathews","year":"1999","journal-title":"Int J Neuropsychopharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1517\/14740338.2.1.21","article-title":"Neuroleptic malignant syndrome induced by atypical antipsychotics","volume":"2","author":"Farver","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"B10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1592\/phco.28.4.530","article-title":"Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations","volume":"28","author":"Picard","year":"2008","journal-title":"Pharmacotherapy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1177\/1060028016657553","article-title":"Neuroleptic malignant syndrome","volume":"50","author":"Pileggi","year":"2016","journal-title":"Ann Pharmacother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00023210\u2013200923060-00003","article-title":"Neuroleptic malignant syndrome associated with atypical antipsychotic drugs","volume":"23","author":"Trollor","year":"2009","journal-title":"CNS Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2174\/157488609787354387","article-title":"Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?","volume":"4","author":"Odagaki","year":"2009","journal-title":"Curr Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1176\/ajp.154.8.1156","article-title":"Case-control study of neuroleptic malignant syndrome","volume":"154","author":"Sachdev","year":"1997","journal-title":"Am J Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1017\/S1461145704004924","article-title":"Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia","volume":"8","author":"Gefvert","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"B16","first-page":"295","article-title":"Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients","volume":"50","author":"Rosebush","year":"1989","journal-title":"J Clin Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2018.00718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T05:12:58Z","timestamp":1545109978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2018.00718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":16,"alternative-id":["10.3389\/fpsyt.2018.00718"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2018.00718","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"article-number":"718"}}